AstraZeneca CEO Says Company Can Grow Without Major Acquisitions
AstraZeneca (AZN) CEO Pascal Soriot stated during a Bloomberg interview that the pharmaceutical company can continue to grow through internal development and strategic partnerships without relying on major acquisitions. He emphasized confidence in AstraZeneca's current pipeline, innovation capabilities, and financial strength as sufficient drivers for future growth beyond the end of this decade. Soriot’s comments suggest a shift away from large-scale M&A activity that has historically been used by pharmaceutical firms to expand their portfolios or geographic reach. Instead, he highlighted the importance of organic development and collaboration in sustaining long-term value creation.
Tickers: $AZN
Topics: corporate strategy M&A pharmaceuticals